Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE — María‐Victoria Mateos (2021) | RDL Network
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Thierry Façon, Jae Hoon Lee, Philippe Moreau, Rubén Niesvizky, Meletios A Dimopoulos, Roman Hájek, Luděk Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten‐Kumeli, Muhtarjan Osman, Bruno Paiva, Jesús F. San Miguel
Salomon Manier, Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksaç, Thierry Façon
María‐Victoria Mateos, Michèle Cavo, Joan Bladé, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Maria Krevvata,
María‐Victoria Mateos, Meletios A Dimopoulos, Michèle Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Polina Kaplan, Luděk Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Christopher Chiu, Jianping Wang, Robin Carson,
Discussion(0)
No comments yet. Be the first to comment.